Showing 881 - 900 results of 971 for search '"Radiotherapy"', query time: 0.05s Refine Results
  1. 881
  2. 882

    Synergistic strategies for glioblastoma treatment: CRISPR-based multigene editing combined with immune checkpoint blockade by Xiaolin Liu, Xiao Liu, Xiaonan Luo, Maorong Zhu, Nannan Liu, Juan Li, Qi Zhang, Cheng Zou, Yuxin Wu, Zhengcong Cao, Shuangxin Ma, Weizhong Wang, Guangzhao Yang, Jintao Gu, Wei Liu, Meng Li, Anan Yin, Yalong He, Wei Lin

    Published 2025-02-01
    “…Abstract Glioblastoma (GBM) is a primary brain tumor known for its high levels of aggressiveness and resistance to current treatments such as radiotherapy and chemotherapy. As a result, there is a pressing need for innovative therapeutic approaches to combat GBM. …”
    Get full text
    Article
  3. 883

    Ionizing radiation and photodynamic therapy lead to multimodal tumor cell death, synergistic cytotoxicity and immune cell invasion in human bladder cancer organoids by Annabell Reinhold, Annegret Glasow, Sandra Nürnberger, Annett Weimann, Lucie Telemann, Jens-Uwe Stolzenburg, Jochen Neuhaus, Mandy Berndt-Paetz

    Published 2025-02-01
    “…Background: Photodynamic therapy (PDT) and radiotherapy using ionizing radiation (IR) are promising options for organ-preserving treatment of bladder cancer (BCa). …”
    Get full text
    Article
  4. 884

    A high-valence bismuth(V) nanoplatform triggers cancer cell death and anti-tumor immune responses with exogenous excitation-free endogenous H2O2- and O2-independent ROS generation by Yizhang Tang, Xujiang Yu, Liangrui He, Meng Tang, Wenji Yue, Ruitong Chen, Jie Zhao, Qi Pan, Wanwan Li

    Published 2025-01-01
    “…NaBiVO3-PEG intravenously administered can efficiently accumulate at the tumor site for further real-time computed tomography monitoring, immunotherapy, or alternative synergistic immune-radiotherapy. Overall, this work offers a nanomedicine based on high-valence bismuth(V) nanoplatform and underscores its great potential for cancer immunotherapy.…”
    Get full text
    Article
  5. 885

    Cyclooxygenase-2/prostaglandin E2 inhibition remodulated photodynamic therapy-associated immunosuppression for enhanced cancer immunotherapy by Tao Xu, Kehan Liu, Shuqi Mi, Yao Yao, Mengyao Zhang, Shujuan Xue, Feng Zhi, Sally-Ann Cryan, Dawei Ding

    Published 2025-04-01
    “…This study sets an intriguing example for overcoming the COX-2/PGE2 pathway-exacerbated immunosuppression alongside immune activation, thus enhancing synergistic cancer immunotherapy potentiated by various ROS-producing therapies (e.g., PDT and radiotherapy) and chemotherapy.…”
    Get full text
    Article
  6. 886

    Highlights of Thirty-Year Experience of CO2 Laser Use at the Florence (Italy) Department of Dermatology by Piero Campolmi, Paolo Bonan, Giovanni Cannarozzo, Andrea Bassi, Nicola Bruscino, Meena Arunachalam, Michela Troiano, Torello Lotti, Silvia Moretti

    Published 2012-01-01
    “…Tumor recurrence is minor compared with radiotherapy or surgery. This method is a valid alternative to surgery and/or diathermocoagulation for microsurgery of soft tissues. …”
    Get full text
    Article
  7. 887

    Breast cancer patients with a pre-existing mental illness are less likely to receive guideline-recommended cancer treatment: A systematic review and meta-analysis by Katie Elliott, Emily Haworth, Iakov Bolnykh, R. Hamish McAllister-Williams, Alastair Greystoke, Adam Todd, Linda Sharp

    Published 2025-02-01
    “…Meta-analysis revealed that patients with mental illnesses were significantly less likely to receive guideline-recommended treatments (OR = 0.78, 95 % CI 0.72–0.83, N = 5), chemotherapy (OR = 0.56, 95 % CI 0.34–0.78, N = 6), or radiotherapy (OR = 0.79, 95 % CI 0.66–0.93, N = 5). They were also significantly more likely to undergo mastectomy instead of breast-conserving surgery (OR = 1.38, 95 % CI 1.24–1.52, N = 4). …”
    Get full text
    Article
  8. 888

    Functional outcomes in early (T1/T2) supraglottic cancer: a systematic review by Benjamin van der Woerd, Krupal B. Patel, Anthony C. Nichols, Kevin Fung, John Yoo, S. Danielle MacNeil

    Published 2018-12-01
    “…Abstract Objectives Organ preserving surgery (OPS) and radiotherapy (RT) are both accepted treatment options for early stage supraglottic cancer (SGC). …”
    Get full text
    Article
  9. 889

    Comparison of prophylactic topical application of Cryptomphalus aspersa secretion versus betamethasone for telecobalt radiation-induced skin reactions in locally advanced head and... by Ramashish Kumar, Ashok Chauhan, Sovan Sarang Dhar, Nitish Kumar

    Published 2025-02-01
    “…Radiation-induced acute skin reaction is of major concern during and after definitive course of radiotherapy. Prevention and treatment of these reactions play an important role in the completion of the prescribed course of EBRT within stipulated time period while maintaining the quality of life. …”
    Get full text
    Article
  10. 890

    Patterns of regional recurrence in papillary thyroid cancer patients with lateral neck metastases undergoing neck dissection by Jason J. Xu, Eugene Yu, Caitlin McMullen, Jesse Pasternak, Jim Brierley, Richard Tsang, Han Zhang, Antoine Eskander, Lorne Rotstein, Anna M. Sawka, Ralph Gilbert, Jonathan Irish, Patrick Gullane, Dale Brown, John R. de Almeida, David P. Goldstein

    Published 2017-05-01
    “…Significant predictors of regional failure were the total number of suspicious nodes on preoperative imaging (p = 0.029), largest positive node on initial neck dissection (p < 0.01), and whether patients received adjuvant radiotherapy (p = 0.028). The 5-year ipsilateral regional recurrence rate was 8 and 9% with selective and comprehensive dissection, respectively (p = 0.89). …”
    Get full text
    Article
  11. 891

    Clinicopathological characteristics and survival outcomes of women aged ≤45 and >45 years with endometrial adenocarcinoma in tertiary referral hospital: a 21-year cohort study by Tarinee Manchana, Pinyada Panyavaranant, Juthamas Rattanachaipipat

    Published 2025-01-01
    “…Objective This study aimed to compare clinicopathological characteristics and oncological outcomes in patients with endometrial cancer aged ≤45 and &gt;45 years, with a focus on identifying distinct traits and prognostic factors in younger patients.Design A retrospective cohort study.Setting The study was conducted at King Chulalongkorn Memorial Hospital, Bangkok, Thailand, with a restricted study population from 1996 to 2016.Participants A total of 1114 patients diagnosed with endometrial cancer and underwent surgery were strictly selected, excluding those who had received primary radiotherapy or had uterine sarcoma. Among the population, 188 patients (16.9%) were ≤45 years old and 926 patients (83.1%) were &gt;45 years old.Outcome measures The primary outcome measures were disease-free survival (DFS) and overall survival (OS) at 5, 10 and 15 years, with an analysis of survival rates based on patient age groups and prognostic factors.Results Younger patients (≤45 years) displayed significantly higher rates of obesity, nulliparity and polycystic ovary syndrome (PCOS), as well as favourable pathological characteristics such as well-differentiated tumours and lower rates of myometrial invasion. …”
    Get full text
    Article
  12. 892
  13. 893

    Personalized treatment strategies for breast adenoid cystic carcinoma: A machine learning approach by Sakhr Alshwayyat, Mahmoud Bashar Abu Al Hawa, Mustafa Alshwayyat, Tala Abdulsalam Alshwayyat, Siya sawan, Ghaith Heilat, Hanan M. Hammouri, Sara Mheid, Batool Al Shweiat, Hamdah Hanifa

    Published 2025-02-01
    “…The 5-year overall survival (OS) rates were highest for surgery + radiotherapy (RT) (94.9 %) and lowest for surgery + chemotherapy (CTX) + RT (80.1 %). …”
    Get full text
    Article
  14. 894
  15. 895

    Prognostic Role of Monocytic Myeloid-Derived Suppressor Cells in Advanced Non-Small-Cell Lung Cancer: Relation to Different Hematologic Indices by Asmaa M. Zahran, Helal F. Hetta, Zeinab Albadry M. Zahran, Alaa Rashad, Amal Rayan, Dalia O. Mohamed, Zeinab Ahmed Abd Elhameed, Salah M. Khallaf, Gaber El-Saber Batiha, Yasir Waheed, Khalid Muhammad, Hanaa Nafady-Hego

    Published 2021-01-01
    “…We recruited 40 cases of advanced NSCLC, stages III and IV, aged>18–<70 years old, and eligible to receive chemotherapy with or without radiotherapy, along with 20 healthy controls of comparable age and sex; after diagnosis and staging of patients, blood samples were collected for flow cytometric detection of Mo-MDSCs. …”
    Get full text
    Article
  16. 896
  17. 897

    Outcomes of oncologic arthroplasty in children and adolescents with malignant limb tumors: a systematic review by Vyacheslav I. Zorin, Sergei V. Vissarionov, Alexandr Y. Makarov, Timofey S. Rybinskikh, Kristina N. Rodionova

    Published 2024-12-01
    “…However, the development and refinement of chemotherapy and radiotherapy protocols, along with advances in surgical techniques and implants, have significantly altered the treatment landscape for these patients. …”
    Get full text
    Article
  18. 898

    Computational insights into Sitahe (Leuconotis eugenifolia) bioactive compounds: A promising approach for radioprotection through p53 inhibition by Dian Pribadi Perkasa, Iin Kurnia, Taufik Muhammad Fakih, Teja Kisnanto, Dwi Ramadhani, Harry Nugroho Eko Surniyantoro, Boky Jeanne Tuasikal, Alfian Mahardika Forentin, Mukh Syaifudin

    Published 2025-01-01
    “…The radioprotective potential of Sitahe (Leuconotis eugenifolia) phytochemicals in cancer radiotherapy remains largely unexplored. In this study, in silico docking simulations were conducted to systematically assess the ability of key phytochemicals from Sitahe to modulate p53 activity, a critical gene in DNA repair and cancer therapy. …”
    Get full text
    Article
  19. 899

    Exploiting somatic oncogenic driver alterations in a patient with Li-Fraumeni syndrome– paving the path towards precision medicine: a case report by Carolin Seeling, Sonja Dahlum, Ralf Marienfeld, Vera Jan, Brigitte Rack, Uwe Gerstenmaier, Ambros J. Beer, Regine Mayer-Steinacker, Wolfgang Thaiss, Thomas F. E. Barth, Thomas Seufferlein, Nadine T. Gaisa, Stephan Stilgenbauer, Wolfgang Janni, Reiner Siebert, Hartmut Döhner, Verena I. Gaidzik

    Published 2025-01-01
    “…Due to impaired DNA damage repair, conventional cytotoxic therapies or radiotherapy should be avoided whenever feasible to mitigate the high incidence of treatment-related secondary malignancies in these patients. …”
    Get full text
    Article
  20. 900

    CDK4/6 inhibitors promote PARP1 degradation and synergize with PARP inhibitors in non-small cell lung cancer by Carlos M Roggero, Anwesha B Ghosh, Anvita Devineni, Shihong Ma, Eliot Blatt, Ganesh V. Raj, Yi Yin

    Published 2025-02-01
    “…Preclinical studies indicate that CDK4/6i may collaborate by influencing DNA damage repair pathways during radiotherapy. Since PARP1 expression was also significantly upregulated in NSCLC, we analyzed the efficacy of combining PARP1 and CDK4/6 inhibition in NSCLC models. …”
    Get full text
    Article